GENSIGHT BIOLOGICS S.A.
26 October 2023
- Financial press releases
- Current cash runway to mid-November 2023; August financing's 2nd tranche for €4m conditioned notably to 2nd batch successful manufacturing expected early November
- New RECOVER Phase III trial design endorsed overall by the EMA; trial expected to start in Q2 2024
- Successful 1st GMP batch manufactured in September; 2nd batch ongoing with results expected early November 2023
- Discussions on further financing and strategic options including M&A ongoing
Attachments
- Original Link
- Original Document
- Permalink
Disclaimer
Gensight Biologics SA published this content on 26 October 2023 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 26 October 2023 16:09:56 UTC.
